Evaluation and Treatment of Stage I and II Thymoma  by Detterbeck, Frank C.
MALIGNANCIES OF THE THYMUS
Evaluation and Treatment of Stage I and II Thymoma
Frank C. Detterbeck, MD
Abstract: Thymomas are relatively uncommon. Nevertheless, an
accumulation of studies (mostly retrospective, single-institution se-
ries) have made it important to approach this disease in a knowl-
edgeable, evidence-based fashion. This begins with the approach to
evaluation of a patient with an anterior mediastinal mass, in whom
a reliable clinical diagnosis is usually possible in experienced
centers. Surgical resection is the mainstay of treatment, and every
effort must be made to achieve a complete resection.
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Thymic malignancies have often been poorly understood,partly because of their relative infrequency. However,
other factors have contributed to a lack of appreciation for the
data that has been accumulated about this disease. The famil-
iarity of the normal thymus to cardiac surgeons contributes to
a sense of complacency when approaching a patient with a
thymic malignancy. The misleading and inappropriate term
“benign” thymoma has also perpetuated a lack of diligence in
reviewing and understanding the available literature. This
article reviews data that pertains to defining a clinical ap-
proach to patients and to treatment, with a focus on early-
stage thymic tumors.
CLINICAL PRESENTATION AND DIAGNOSIS
Thymomas occur in patients of all ages, ranging from 8
months1 to 94 years.2,3 The age distribution of patients with a
thymoma shows a broad peak between approximately 35 and
70 years.4 The reported median age is approximately 54 years
among studies of 100 patients.3,5–10,11 As a group, patients
with myasthenia gravis (MG) tend to present at a slightly
younger age than patients without MG, but there is broad
overlap in the age distributions between these two groups.4
The ratio of men to women in series of thymomas is
approximately equal. There are slightly more women than
men in the older age groups.4 This appears to be primarily
the result of a slight increase in the proportion of women
without MG who are found to have a thymoma among the
older age groups.4
Approximately 40 to 45% of patients present with MG,
which is the most common “parathymic” condition.12,13
These also include hypogammaglobunlinemia and red cell
aplasia. Approximately 1/3 of patients are asymptomatic,
whereas about 1/3 have symptoms typical of a mass in the
chest (cough, dyspnea, chest pain).4
Thymoma accounts for 50% of anterior mediastinal
masses in patients older than 50, and 70% if substernal
goiters are excluded, which are usually easy to recognize.
However, for women between the age of 20 to 40, lym-
phoma accounts for approximately 50% of anterior medi-
astinal masses, with an increasing minor proportion of
thymoma from about 15% at age 20 to 40% at age 40. A
similar proportion of men aged 20 to 40 have thymomas;
the diagnoses are mixed in the rest with no dominant
etiology of the anterior mediastinal mass. Thymomas are
relatively uncommon below age 20. These proportions can
be used to guide the approach to a patient with an anterior
mediastinal mass.
In many instances, a clinical diagnosis of thymoma is
sufficient. The presence of a parathymic condition and an
anterior mediastinal mass reliably establishes a clinical diag-
nosis of thymoma.4 Furthermore, it is not necessary to estab-
lish a preoperative diagnosis of a small, resectable tumor in
the anterior mediastinum with radiographic imaging typical
of a thymoma. A definitive diagnosis is needed primarily
when a presumed thymoma is so extensive that it is thought
best treated with a nonoperative approach or with preopera-
tive chemoradiotherapy, or in instances where lymphoma is
considered to be a strong possibility.
Pathologic confirmation of the diagnosis of thymoma
can be achieved from a needle aspiration (FNA) or via an
open surgical biopsy. The success rate of FNA in establishing
the diagnosis is reported to be approximately 60%.10,14–16 It
appears that in many of these cases, a core biopsy or multiple
passes were performed to have an adequate sample of tissue.
In one of the more detailed studies, an FNA had a sensitivity
of 71%, a specificity of 94%, a false positive rate of 23%, and
a false negative rate of 8%.14 The success rate of an open
surgical biopsy in establishing the diagnosis is reported to be
approximately 90%.10,16 The reliability of establishing the
histologic subtype of thymoma from a limited biopsy may be
difficult, because of the characteristic variability in morpho-
logic appearance within a thymoma.17 However, the histo-
logic subtype is of questionable value in determining optimal
therapy.18
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There exists a widespread dogma that biopsy of a
presumed thymoma should not be undertaken because it risks
spreading the tumor into the pleural space or the needle tract
or biopsy site.19 However, there is little data to substantiate
this. No case of seeding of a needle tract or incisional biopsy
site has ever been reported. Three instances of a recurrence at
the thoracotomy site used for resection have been men-
tioned.16,20 A large series of 136 patients found that there was
a trend to better survival in those patients who underwent a
preresection biopsy by multivariate analysis (p  0.056).8
Furthermore, it is standard policy to obtain a biopsy in cases
of larger tumors suspected to be a thymoma in many centers
with extensive experience in thymoma.10,15,16,21–24
TREATMENT
Natural History and Clinical Behavior
The prognosis without treatment (i.e., natural history)
of patients with a thymoma has not been well studied. The
clinical progression of disease appears to be rather indolent in
most cases. In 31 patients in whom prior films were available,
77% demonstrated a thymoma 1 to 26 years previously
(mean, 6 years).25 A case has been reported documenting
slow growth of a thymoma over 21 years.26 The indolent
course is also corroborated by the long interval to recurrence
(1–32 years, average 5 years) among treated patients who
develop further manifestations of disease.
Although thymomas are generally indolent tumors,
they do have the ability to metastasize to the pleura and
pericardium and to distant sites. A study of metastases re-
vealed that 4% of 207 patients referred to a surgery clinic had
lymph node or distant metastases at the time of presentation,
and another 16% developed lymph node or distant metastases
during the course of their disease.27 Of those who developed
metastases, nodes were involved in 14% of patients, pleural
or pericardial metastases in 56%, and distant sites in 31%.27
The distant sites involved 1/3 lung, 1/3 liver, 1/6 bone, and
1/6 kidney, brain, or bone marrow.27 Among each stage at
presentation (including stage I), some patients subsequently
developed distant metastases in a classic study of 200 patients
by Verley and Hollmann,28 and this has been confirmed by
others.29 In every large series with long-term follow-up,
metastases have been reported for each stage or histologic
appearance of thymoma. This data demonstrates that all
thymomas are malignant tumors (i.e., have the ability to
metastasize) despite a generally protracted course.4,30 The
misleading term “benign thymoma” is no longer appropriate
given the available data.30
Surgical Resection
Survival after Surgical Resection
Overall survival of surgical series of 100 patients
with thymoma is shown in Table 1. The 5-year survival rates
are quite good, even for patients with stage III and IV disease.
The 10-year survival rates are approximately 90% and 70%
for stage I and II, and 55% and 35% for stage III and IVa.
Overall survival rates at 15 years for stage I, II, III, and IV
disease are reported as 78%, 73%, 30%, and 8%, respective-
ly.31 Representative survival curves from one of the largest
TABLE 1. Overall Survival after Resection of a Thymoma
Overall Survival
References n Years Included
Treatment (%) 5-Yr Survival (%) 10-Yr Survival (%)
R0 Ch RT I II III IVa I II III IVa
Regnard et al.31 307 55–93 85 6 52 89 87 68 66 80 78 47 30
Maggi et al.21 241 59–88 88 — — 89 71 72 59 87 60 64 40
de Jong et al.3 232 94–03 41 10a 33a 83 89 58 56 — — — —
Verley and Hollmann28 200 55–82 — Few Most 85 60 ——33—— 80 42 ——23——
Chen et al.48 200 69–96 — 4 28 97 94 53 24 90 82 37 —
Ströbel et al.49 179 — 77a 12 25 100 100 87 66 100 91 84 47
Park et al.50 150 92–02 69 — — 100 88 63 23 — — — —
Nakahara et al.1b 141 57–85 80 Few 84 100 92 88 47c 100 84 77 47c
Wilkins et al.8 136 57–97 68 7 37 84 66 63 40 75 50 44 40
Blumberg et al.10 118 49–93 73 32 58 95 70 50 100 86 54 26d —
Quintanilla-Martinez et al.42 116 39–90 94 1 26 100 100 70 (70)e 100 100 60 (0)e
Pan et al.51b 112 61–91 80 — — 94 85 63 41 87 69 58 22
Ogawa11b 103 79–98 100 — 100 100 90 56 — 100 90 48 —
Elert et al.52 102 57–87 — — — 83 90 46 —e — — — —
Kondo et al.53 100 73–01 84 28 37 100 100 69 57c 100 100 69 —
Averagef 2437 93 85 65 53 90 75 56 38
Inclusion criteria: results of 100 patients, with results by Masaoka stage.
a Estimated from data provided.
b Thymic carcinoma excluded.
c Stage IVa, b.
d 9-yr survival data.
e 5 patients.
f Excluding values in parentheses.
Ch, chemotherapy; R0, complete resection; RT, radiotherapy.
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studies are shown in Figure 1. These survival rates include
patients undergoing a partial resection (among the stage III or
IV thymomas).
Significantly better survival has been noted in patients
who underwent complete resection by every large study
examining this issue.1,2,5,8–10,21,31–34 It is remarkable that the
long-term survival of patients with a stage III thymoma is
similar to that of those with a stage I thymoma, provided a
complete resection is performed.31,35 These findings imply
that a complete resection may be the most important prog-
nostic factor, and that every effort must be made at the time
of surgery to accomplish this.
Resectability
The ability to perform a grossly and microscopically
complete resection, varies with the stage of the thymoma. It
is uniformly high in patients with stage I thymomas, and high
in most reports in patients with stage II thymomas as well
(Table 2). Approximately half of patients with stage III and
only about a quarter of patients with stage IV tumors can be
completely resected on average. However, there is wide
variation in the reported resectability rates between studies in
patients with higher stage thymomas (from 43 to 100% for
stage II, 0 to 89% for stage III, and 0 to 78% for stage IV).
The most likely explanation appears to be differences in
philosophy about the role of subtotal resection between dif-
ferent centers, and the willingness of surgeons to undertake
more extensive operations (such as resection of the superior
vena cava).
Cause of Death
Overall, approximately 50% of the deaths are due to
thymoma or due to the treatment.4,36 Approximately 20% of
deaths have been due to MG, and 10% to autoimmune
disorders associated with thymomas. The rest of the deaths
have been attributed to unrelated conditions, including other
malignancies.4 Whether deaths due to second primary malig-
nancies should be viewed as unrelated is debatable, however,
because many studies have noted a higher than expected
incidence of second primary malignancies in patients with a
thymoma (average 15%, range, 9–27% of patients with
thymoma).8,10,12,37–41
Studies reporting death rates by stage have fairly con-
sistently shown death rates from thymoma of 1% (range,
0–2%) for patients with stage I, 8% (range, 3–12%) for those
with stage II, 23% (range, 10–36%) for those with stage III,
and 50% (range, 36–67%) for those with stage IV tu-
mors.1,19,28,31,42 The percentage of all deaths that are due to
thymoma is 1% (range, 0–3%) of deaths in patients with
stage I disease, 32% (range, 20–50%) of deaths in patients
with stage II, 57% (range, 50–71%) of deaths in patients with
stage III, and 77% (range, 64–100%) of deaths in patients
with stage IV disease.19,31,42 In addition, the rate of death
from thymoma is 5% (range, 5–6%) for patients who under-
went a complete resection (R0), 38% (range, 31–44%) for
subtotal resection (R1,2), and 67% (range, 50–83%) of pa-
tients who underwent only a biopsy.1,43
Recurrence Rates and Patterns
Local recurrence is by far more common than a distant
recurrence. Approximately half of the local recurrences in-
volve the pleural space or the lung, with the typical appear-
ance being a nodule under the parietal pleura.4 Half of the
local recurrences involve the mediastinum (which includes
the pericardium, where pericardial nodules are also common).
Liver and bone are the two most common sites of distant
metastases.4
The rate of recurrence is a better measure of outcome
after treatment of thymoma than overall survival, given the
indolent behavior of many of these tumors.36 Recurrence
rates taken from a comprehensive review4 are shown in
Figure 2.4 Average recurrence rates are low for Masaoka
stage I tumors (3%), but increase progressively to 11 and
30% for stage II and III tumors.
The indolent behavior of thymic tumors is demon-
strated by the average time to recurrence of approximately
5 years.2,8,10,21,29,31 The mean time to recurrence was 10
years in patients with a stage I thymoma, compared with 3
FIGURE 1. Overall survival according to Masaoka Stage.
Reproduced with permission from J Thorac Cardiovasc Surg.31
TABLE 2. Rate of Complete Resection of a Thymoma
by Stage
References n I II III IVa IVb
Regnard et al.31 307 100 100 50 63
Fang et al.54 204 100 100 75
Okumura et al.5a 194 100 100 89 0 0
Nakahara et al.1a 141 100 100 73 0
Blumberg et al.10 118 100 73 56 78 —
Kondo et al.53 100 100 100 72 50 47
Curran et al.7a 99 100 100 20 — —
Masaoka et al.43a 96 100 100 64 0 (0)b
Gamondès et al.55a 65 100 43 0 13
Kaiser and Martini23 59 100 63 21 — —
Averagec 1383 100 88 49 29
Inclusion criteria: studies of 50 patients reporting stage specific resectability rates
in patients undergoing primary surgery.
a Thymic carcinoma excluded.
b 5 patients.
c Excluding values in parentheses.
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years in patients with a stage II to IV thymoma.28 How-
ever, because recurrences can be seen 10 to 20 years later,
and because surgical resection of a local recurrence affords
good survival,4,10,29 surveillance of a patient with a resected
thymoma should probably extend at least 20 years.36
Adjuvant Radiotherapy
In the past, adjuvant radiotherapy (RT) was given
frequently to patients with thymoma. Over time, however,
data has emerged that this is of limited (if any) benefit in
patients who have been completely resected.44–47 Data taken
from series that reported results by stage and for completely
resected patients is shown in Figure 3. Several meta-analyses
have also suggested no benefit in completely resected pa-
tients.44–47 However, these are not randomized series, and
selection of patients at higher risk for recurrence may have
been more likely in the RT treatment cohorts. Although the
propensity to local recurrence provides a rationale for adju-
vant RT, it must be remembered that most of these local
recurrences involve pleural or pericardial implants, which are
not necessarily contiguous with the original tumor location.9
Given the nonrandomized data suggesting little benefit, it is
probably best to omit RT for a completely resected stage I or
II thymoma.
CONCLUSIONS
The clinical presentation, radiographic appearance, and
knowledge of the proportions of diagnoses of anterior medi-
astinal masses allow a very reliable clinical diagnosis of
thymoma to be made in the majority of patients. Although a
preoperative biopsy can sometimes be useful, it is generally
not needed. Despite a generally indolent behavior, all thymo-
mas are malignant in nature and in general should be treated.
Surgical resection is the mainstay of treatment, particularly
for stage I and II thymomas. Long-term survival and free-
dom-from-recurrence rates are excellent when the tumor is
completely resected, and adjuvant RT has little role for
completely resected, early stage thymomas.
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